About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 4NCT02103257

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lu...

Lead sponsor: Betta Pharmaceuticals Co., Ltd.•31 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Helong Zhang, MD

CONTACT

Sponsors

Lead Sponsor

Betta Pharmaceuticals Co., Ltd.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT)
•Patients must have previously untreated locally advanced or metastatic NSCLC
•EGFR activating mutation (exon 19 deletion, L858R) is required
•Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1

Exclusion Criteria

•Prior chemotherapy or treatment with gefitinib, erlotinib, or other drugs that target EGFR
•Patients with wild-type EGFR
•Any other investigational agents are not permitted
•Any evidence of interstitial lung disease

Related studies

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

NCT07660627 · Esophageal Adenocarcinoma, Gastric Cancer, and more

RECRUITINGPhase 1/2

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more

RECRUITINGPhase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440 · Colorectal Cancer, Colorectal Neoplasms, and more

RECRUITINGPhase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

NCT04521764 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 29, 2015Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment192

Start dateMar 2014

Last updatedApr 29, 2015

Condition

EGFR Positive Non-small Cell Lung Cancer Adenocarcinoma

Locations shown

First Hospital of Lanzhou University

Lanzhou, Gansu

Lanzhou military region general hospital

Lanzhou, Gansu

General Hospital of Guangzhou Military Command

Guangzhou, Guangdong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 29, 2015Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions